Factor VIII inhibitors in hemophilia A: rationale and latest evidence

被引：170
作者：
Witmer, Char [1 ,2 ]
Young, Guy [1 ]
机构：
[1] Childrens Hosp Philadelphia, Div Hematol, Civ Ctr Blvd,CTRB 11th Floor,Room 11026, Philadelphia, PA 19104 USA
[2] Childrens Hosp Angeles & Univ So Calif Keck Sch M, Div Hematol Oncol, Los Angeles, CA 19104 USA
来源：
THERAPEUTIC ADVANCES IN HEMATOLOGY | 2013年 / 4卷 / 01期
关键词：
FVIII; FVIII alloantibodies; hemophilia A; immune tolerance; inhibitors; risk factors;
D O I：
10.1177/2040620712464509
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Factor VIII (FVIII) replacement therapy is the foundation of treatment in hemophilia A and is effective unless a patient develops an alloantibody (inhibitor) against exogenous FVIII. Inhibitor development is currently the most significant treatment complication seen in patients with hemophilia and is associated with considerable morbidity and a decreased quality of life. The development of an inhibitor is the result of a complex interaction between a patient's immune system and genetic and environmental risk factors. The mainstay of treatment is the eradication of the inhibitor through immune tolerance. This review summarizes the current evidence regarding inhibitor risk factors, eradication, and hemostatic bypassing agents.
引用
收藏
页码：59 / 72
页数：14
相关论文
共 121 条
[1]   FREQUENCY OF INHIBITOR DEVELOPMENT IN HEMOPHILIACS TREATED WITH LOW-PURITY FACTOR-VIII [J].
ADDIEGO, J ;
KASPER, C ;
ABILDGAARD, C ;
HILGARTNER, M ;
LUSHER, J ;
GLADER, B ;
ALEDORT, L .
LANCET, 1993, 342 (8869) :462-464
[2]  
Aledort LM, 1998, HAEMOPHILIA, V4, P68
[3]   Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia [J].
Astermark, J .
HAEMOPHILIA, 2006, 12 :52-60
[4]   Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A [J].
Astermark, J ;
Oldenburg, J ;
Pavlova, A ;
Berntorp, E ;
Lefvert, AK .
BLOOD, 2006, 107 (08) :3167-3172
[5]   The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development [J].
Astermark, J ;
Berntorp, E ;
White, GC ;
Kroner, BL .
HAEMOPHILIA, 2001, 7 (03) :267-272
[6]   A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study [J].
Astermark, Jan ;
Donfield, Sharyne M. ;
DiMichele, Donna M. ;
Gringeri, Alessandro ;
Gilbert, Steven A. ;
Waters, Jennifer ;
Berntorp, Erik .
BLOOD, 2007, 109 (02) :546-551
[7]   Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A [J].
Astermark, Jan ;
Oldenburg, Johannes ;
Carlson, Joyce ;
Pavlova, Anna ;
Kavakli, Kaan ;
Berntorp, Erik ;
Lefvert, Ann-Kari .
BLOOD, 2006, 108 (12) :3739-3745
[8]   Polymorphisms in genes involved in autoimmune disease and the risk of FVIII inhibitor development in Italian patients with haemophilia A [J].
Bafunno, V. ;
Santacroce, R. ;
Chetta, M. ;
D'Andrea, G. ;
Pisanelli, D. ;
Sessa, F. ;
Trotta, T. ;
Tagariello, G. ;
Peyvandi, F. ;
Margaglione, M. .
HAEMOPHILIA, 2010, 16 (03) :469-473
[9]  
Berntorp E, 2000, HAEMATOLOGICA S, V85, P50
[10]  
Berntorp Erik, 2000, Haematologica, V85, P48
12345678910